AI assistant
Moderna, Inc. — Director's Dealing 2022
Mar 3, 2022
30610_dirs_2022-03-03_d9a7d7bd-db9e-4cac-bf3f-f6102d6ab475.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-03-01
Reporting Person: Andres Juan (See remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-02 | Common Stock | M | 2000 | $14.22 | Acquired | 11069 | Direct |
| 2022-03-02 | Common Stock | S | 2000 | $150.00 | Disposed | 9069 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-01 | Stock Option (Right to Buy) | $149.52 | A | 32525 | Acquired | 2032-03-01 | Common Stock (32525) | Direct |
| 2022-03-01 | Restricted Stock Units | $0 | A | 8019 | Acquired | Common Stock (8019) | Direct | |
| 2022-03-02 | Stock Option (Right to Buy) | $14.22 | M | 2000 | Disposed | 2028-02-28 | Common Stock (2000) | Direct |
Footnotes
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.
F2: 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F4: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.